Lung Cancer
Conference Coverage
Immune-related events with checkpoint inhibitors are manageable
Key clinical point: Inhibitors of CTLA-4 and PD-1/PD-L1 are associated with manageable immune-related adverse events. Major finding: Cutaneous...
News
Pan-AKT inhibitor shrinks tumors in patients with AKT1 mutation
A novel pan-AKT inhibitor shrinks tumors in patients harboring a mutation in AKT1.
Conference Coverage
Experimental LOXO-101 induces regression in several hard-to-treat cancers
Key clinical point:Inhibition of TRK gene fusion products is a novel strategy for treating cancer. Major finding: Three of three patients...
News
Novel EGFR-TKI clears leptomeningeal disease in phase I study
Key clinical point: A tyrosine kinase inhibitor targeted to mutant EGFR showed good activity against leptomeningeal metastases in patients with...
News
Less pneumonitis with IMRT than 3D-CRT for non–small-cell lung cancer
Article
Commentary: Red meat and cancer risk – what your patients should know
The WHO’s classification of processed meat as a carcinogen and red meat as a probable carcinogen could help motivate patients to make healthier...
News
Surgery, dose-escalated chemoradiotherapy yield similar outcomes in NSCLC
Key clinical point: After a complex induction protocol, patients with non–small cell lung cancer (NSCLC) who underwent surgery vs. dose-escalated...
News
FDA expands use of nivolumab to non-squamous NSCLC
News
Targeted therapy brings fresh hope for small-cell lung cancer treatment
Key clinical point: Rovalpituzumab tesirine has single-agent activity in small-cell lung cancer, a malignancy with high unmet need. Major finding...
Conference Coverage
Everolimus makes splash in lung, GI neuroendocrine tumors
Key clinical point: Everolimus significantly delays tumor growth in advanced lung and gastrointestinal neuroendocrine tumors. Major finding:...